FolioLanternBeta
RVMDRevolution Medicines, Inc.

Xiaolin Wang

EVP, Clinical Development at Revolution Medicines, Inc., as of Mar 19, 2026Sold $200K of stock in the past 12 months: 100% under a disclosed plan.

Updated Oct 15, 2026 from SEC filings · covers Oct 16, 2025 to Oct 15, 2026
67K
shares held after the latest filing, Revolution Medicines, Inc.
Vested shares reported on Forms 3, 4 and 5 only. Not the insider's whole wealth.
2K
shares sold, past 12 months
1
days with sales
$200K
largest single day, Mar 17, 2026
1
company filed for

Share of stake sold at Revolution Medicines, Inc. is not shown: the holdings do not reconcile with the filings. Why

Selling by month

Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNovDecJanFebMar 2026: $200K under a disclosed plan$200KMarAprMayJunJulAugSepOct

Pattern

What the filings show, past 12 months. Nothing here rates or predicts.

Roles from filings

Every company we track where this person has filed, newest filing first.

CompanyTitleFirst filingLatest filing
Revolution Medicines, Inc. (RVMD)EVP, Clinical DevelopmentMar 8, 2021Mar 19, 2026

Recent filings

The last 2 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.

This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.